BeiGene’s Tislelizumab Receives the NMPA’s Approval as a 2L Treatment for Esophageal Squamous Cell Carcinoma
- The approval is based on a P-III RATIONALE 302 study assessing the efficacy and safety of tislelizumab vs CT as a 2L treatment in 512 patients in a ratio (1:1) with LA or metastatic ESCC across 11 countries
- The 1EPs is OS in the IIT population, whereas 2EPs is OS in patients with high PD-L1 expression and other 2EPs include PFS, ORR, and DoR
- This marks the eighth approved indication for the therapy in China. Tislezumab is currently under regulatory review in the US and the EU as a 2L treatment for patients with locally advanced or metastatic ESCC
Ref: BeiGene | Image: BeiGene
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.